Hopman Mark 4

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), sold a total of 2,917 shares in two open-market transactions: 856 shares on 2025-12-02 at $29.34 (proceeds $25,112) and 2,061 shares on 2025-12-04 at $30.66 (proceeds $63,192), for combined proceeds of $88,304. These were sales (not purchases) and the filing indicates they were to cover tax withholding tied to RSU vesting.

Key Details

• Transaction dates and amounts:
  • 2025-12-02: 856 shares sold at $29.34 — $25,112 (F1)
  • 2025-12-04: 2,061 shares sold at $30.66 — $63,192 (F2)
  • Footnote F3: reported weighted average sale price $30.6610; price range $30.02–$31.0024. Full breakdown by price available on request.
• Shares owned after the transactions: not stated in this Form 4 filing.
• Notable footnotes:
  • F1: sales were to cover tax withholding on vested restricted stock units.
  • F2: sales executed pursuant to a Rule 10b5-1 plan adopted May 13, 2025 (prearranged plan).
• Filing timeliness: Form 4 was filed 2026-03-16 for transactions in December 2025 — this appears late relative to the typical two-business-day Form 4 deadline and is flagged as untimely in the filing metadata.

Context
A Rule 10b5-1 plan is a prearranged trading program that lets insiders sell shares on a set schedule regardless of later information; it’s commonly used to avoid the appearance of trading on inside information. Sales to cover tax withholding on RSU vesting are routine and do not necessarily indicate a change in insider sentiment. For investors, purchases typically carry more positive informational weight than routine withholding-driven sales.